SCIENTIFIC BACKGROUND

CACNA1S, RYR1

Scientific Background

Malignant hyperthermia (MH) is a genetic Ca2+ regulatory disorder of skeletal muscle. In genetically predisposed individuals, the administration of volatile anesthetics (fluranes) and depolarising muscle relaxants (e.g., suxamethasone) can lead to a potentially life-threatening hypermetabolism. The symptoms are very variable and range from moderate forms with low severity to a severe, sudden (fulminant) MH crisis. In the early phase, classic signs of a fulminant MH crisis are tachycardia, hypercapnia, hypoxemia and masseter spasms; in the late phase, acidosis, hyperkalemia, rhabdomyolysis and hyperthermia are added. The antidote dantrolene has reduced the mortality rate in MH crises to <5%. The prevalence of MH in the German population is estimated at 1:10,000. The incidence of a fulminant MH crisis is about 1:60.000. In predisposed patients, the administration of trigger substances must be avoided. Without trigger substances, myopathy is usually inapparent.

 

Pathogenic variants in the ryanodine receptor 1 (RYR1) and the dihydropyridine receptor (voltage-dependent L-type calcium channel, CACNA1S) are associated with a predisposition for MH. Heredity is autosomal dominant with incomplete penetrance. Variants in one of these genes could be identified in about 75% of MH families. The detection of a causative variant enables the identification of other relatives at risk by means of target diagnostics. However, so far only about 50 variants have been categorized as causative by the European Malignant Hyperthermia Group (EMHG). In addition, the studies did not identify variants in the RYR1 or CACNA1S gene in all affected patients, so that a negative molecular genetic finding does not rule out the presence of MH. Therefore, where suspicion exists and there are negative genetic findings or if variants of unclear significance are detected, an in vitro muscle contraction test (IVCT) should be performed to confirm the diagnosis.

 

References

Gonsalves et al. 2019, Clin Pharmacol Ther 105:1338

GENES

CACNA1S, RYR1

ASSOCIATED TESTS

How to order

LATEST ARTICLES

Every year on April 25th, DNA Day celebrates the discovery of DNA’s double helix and the advances we’ve made in understanding genetics. D...

Read more

Neurodevelopmental disorders (NDDs) have diverse genetic origins, making diagnosis challenging. A new study analyzing over 1,100 pediatric patients f...

Read more

Colorectal cancer (CRC) remains one of the most prevalent and deadly cancers worldwide, with a significant number of cases presenting at an advanced ...

Read more

Carrier screening is a genetic test designed to identify whether an individual carries a gene with changes (mutations) associated with inherited diso...

Read more

Trisomy 13, also known as Patau syndrome, is a genetic condition in which cells in the body have three copies of chromosome 13 instead of two. The co...

Read more

The human brain develops through a complex series of events, with genes carefully regulating the formation of neurons and glial cells. A recent study...

Read more

Rare diseases affect between 300 and 400 million people worldwide – more than cancer and AIDS combined [1, 2], but despite this, many people face a...

Read more

Rosalind Elsie Franklin was a brilliant and meticulous research scientist whose interdisciplinary work made fundamental contributions to various area...

Read more

February, designated as Cancer Awareness Month, marks a time to reflect on the remarkable progress made in cancer research and to inspire hope for th...

Read more

Introduction Cardiovascular disease (CVD) is a major health issue as it remains a leading cause of death worldwide [1]. CVD is responsible for mor...

Read more